Summary & Overview
HCPCS J9250: Methotrexate Sodium, 5 mg
HCPCS Level II code J9250 designates methotrexate sodium, 5 mg and is used to report the supply or administration of this antimetabolite drug in standardized 5 mg units. Nationally, accurate use of J9250 matters for claims integrity, drug utilization tracking, and reimbursement of chemotherapy and immunomodulatory therapies across outpatient and infusion settings. Common sites where J9250 appears include infusion centers, hospital outpatient departments, physician offices, and outpatient pharmacies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical and billing context, payer coverage considerations, and the types of benchmarks and policy updates typically associated with HCPCS drug codes. The publication highlights standard reporting practices, how units translate to dosing documentation, and where to expect variability in payer policies.
The report does not provide clinical recommendations. Instead, it summarizes how J9250 is used for claims processing, the service types and sites where it commonly appears, and the categories of information—such as utilization benchmarks, prior authorization trends, and billing policy updates—that stakeholders monitor when managing methotrexate dispensing and administration at the national level.
Billing Code Overview
HCPCS Level II code J9250 represents methotrexate sodium, 5 mg supplied for therapeutic use. This code denotes the drug formulation and unit of measure rather than a specific clinical procedure. The service type is pharmaceutical/drug administration when billed in contexts where the medication is furnished; it may also appear on pharmacy or infusion service lines depending on setting and payer rules.
The typical site of service for charges using J9250 includes infusion centers, hospital outpatient departments, physician offices, and outpatient pharmacies when methotrexate is dispensed or administered. Billing using this HCPCS Level II code documents the quantity of methotrexate sodium in 5 mg units provided during the encounter.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9250 (methotrexate sodium, 5 mg) is an adult or pediatric patient with an autoimmune or inflammatory condition requiring low‑dose oral methotrexate for disease control. Common clinical scenarios include a rheumatology clinic treating rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis; a dermatology clinic managing severe psoriasis; or an oncology/supportive care setting dispensing low‑dose oral methotrexate for certain malignancy protocols.
The clinical workflow begins with diagnosis and treatment planning by a prescribing clinician (rheumatologist, dermatologist, pediatrician, or oncologist). Baseline evaluation includes history, physical exam, and laboratory testing (CBC, liver function tests, renal function). The clinician prescribes methotrexate tablets, typically dispensed in weekly doses (commonly 7.5–25 mg weekly, often given as multiple 5 mg tablets). The pharmacy or clinic bills outpatient drug administration or supply using J9250 per 5 mg unit. Follow‑up visits assess efficacy and adverse effects; labs are repeated periodically. Documentation includes indication, dose and frequency, date dispensed or administered, patient counseling, and monitoring plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |